Sinopharm Group Co Ltd

Chart & Performance

D1W1MN

P/E

5.75

P/S

0.09

EPS

2.88

Div Yield, %

5.44%

Shrs. gr., 5y

0.96%

Rev. gr., 5y

11.61%

Revenues

596.57b

+8.05%

Net income

9.05b

-36.89%

CFO

17.17b

-18.08%

Dividend

Jun 16, 20250.72906 HKD/sh

Earnings

Apr 24, 2025

Profile

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

URL

https://www.sinopharmholding.com/

IPO date

Sep 23, 2009

Employees

113,362

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	596,569,565 8.05%	552,147,550 5.97%
Cost of revenue	574,207,650	529,616,610
Unusual Expense (Income)
NOPBT	22,361,915	22,530,940
NOPBT Margin	3.75%	4.08%
Operating Taxes	4,502,309	4,218,377
Tax Rate	20.13%	18.72%
NOPAT	17,859,606	18,312,563
Net income	9,053,760 -36.89%	14,345,442 9.80%
Dividends	(2,558,837)	(2,340,492)
Dividend yield	4.01%	3.78%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	56,526,974	54,633,193
Long-term debt	22,472,244	19,799,500
Deferred revenue		412,973
Other long-term liabilities	4,330,584	3,436,277
Net debt	4,639,447	9,370,609
Cash flow
Cash from operating activities	17,173,030	20,963,787
CAPEX	(1,959,570)	(2,417,529)
Cash from investing activities	(944,535)	(3,589,622)
Cash from financing activities	(7,643,970)	(5,693,481)
FCF	8,557,774	16,237,549
Balance
Cash	63,809,085	55,222,122
Long term investments	10,550,686	9,839,962
Excess cash	44,531,293	37,454,706
Stockholders' equity	98,267,244	87,991,373
Invested Capital	153,899,888	142,775,244
ROIC	12.04%	12.86%
ROCE	11.27%	12.44%
EV
Common stock shares outstanding	3,116,818	3,120,656
Price	20.45 3.07%	19.84 16.98%
Market cap	63,738,928 2.95%	61,913,815 17.34%
EV	114,114,903	117,675,632
EBITDA	26,792,163	26,695,959
EV/EBITDA	4.26	4.41
Interest	2,956,587	3,520,326
Interest/NOPBT	13.22%	15.62%